Details werden geladen...
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease | The Manila Times
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ('Monopar” or the 'Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27-30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.
Ähnliche Seiten
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology | The Manila Times
https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/eikon-therapeutics-presents-data-on-clinical-stage-programs-at-the-2026-annual-meeting-of-the-american-society-of-clinical-oncology/2355073BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/05/28/tmt-newswire/globenewswire/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-with-bipolar-disorders-or-schizophrenia-at-2026-ascp-annual-meeting/2353511
Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis | The Manila T...
https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/johnson-johnson-presents-new-imaavy-nipocalimab-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalised-myasthenia-gravis/2373918Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at ...
https://www.manilatimes.net/2026/06/14/tmt-newswire/globenewswire/upstream-bio-presents-new-responder-analyses-demonstrating-clinically-meaningful-improvements-in-crswnp-in-significant-majority-of-participants-treated-with-verekitug-in-the-phase-2-vibrant-trial-at-eaaci-2026/2365110BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/06/12/tmt-newswire/globenewswire/biocryst-presents-new-clinical-data-and-real-world-evidence-demonstrating-impact-of-hae-portfolio-at-the-2026-european-academy-of-allergy-and-clinical-immunology-annual-meeting/2364354